Bladder Cancer Clinical Trial
Official title:
A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system
and stop cancer cells from growing. It is not yet known which type of BCG is more effective
for bladder cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different types of
BCG in treating patients who have bladder cancer.
OBJECTIVES: I. Compare two strains of BCG (Connaught vs Tice) in terms of efficacy (yearly
relapse rate) and tolerability in patients with Ta or T1 papillary carcinoma of the urinary
bladder or carcinoma in situ of the urinary bladder. II. Assess the role of prior exposition
to mycobacteria (vaccination/Tbc) for BCG treatment efficacy in these patients. III. Define
the role of fever occurrence as a potential indicator for BCG reactivity in these patients.
IV. Evaluate the p53 status of the resected tumors and IL-8 secretion into the urine as
predictive factors of BCG reactivity in these patients. V. Evaluate disease free interval and
disease free survival, time to progression, and overall survival in these patients. VI.
Evaluate quality of life in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
center, T stage (Ta vs T1 vs CIS), and BCG immunization status (positive, i.e., greater than
10 mm diameter vs negative-indeterminate, i.e., less than 10 mm diameter). All patients
undergo complete transurethral resection (TURB) to remove bladder tumors. A Mantoux test is
performed. Patients with stage T1 disease undergo a second resection within 2-4 weeks after
initial TURB. Patients are randomized to receive either BCG Onko-Tice (arm I) or BCG
Connaught (arm II). Both arms receive BCG by catheter beginning 2-14 days after the last
TURB. Patients must hold the BCG in the bladder for 2 hours. BCG is instilled once a week for
6 weeks. Quality of life is assessed before randomization, daily during first and last weeks
of treatment, every 6 months for the first 2 years, and then annually thereafter. Patients
are followed every 6 months for the first 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A minimum of 300 patients will be accrued for this study within 6 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
| Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
| Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
| Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
| Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
| Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
| Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
| Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
| Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
| Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |